Breast Diseases  >>  sunitinib  >>  Phase 1
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
sunitinib / Generic mfg.
NCT00291577 / 2006-000224-13: Study Of SU011248 In Combination With Docetaxel In Patients With Metastatic Breast Cancer

Checkmark P1 data
Feb 2012 - Feb 2012: P1 data
Completed
1
22
Europe
Sunitinib (Sutent), Sutent, Taxotere
Pfizer
Breast Neoplasms
10/08
02/09
NCT00372424 / 2006-001151-35: Study Of SU011248 In Combination With Docetaxel And Trastuzumab In Patients With Advanced Breast Cancer HER-2 Positive

Completed
1
26
Europe
Herceptin, trastuzumab, Sunitinib, Sutent, Taxotere, docetaxel
Pfizer
Breast Cancer
09/11
09/11
CRIZENT, NCT02074878: Crizotinib and Sunitinib in Metastatic Breast Cancer

Terminated
1
3
US
Crixotinib 200 mg and Sunitinib Cohort 1, Crizotinib (Xalkori) 200 mg twice daily, Sunitinib (Sutent) 25.0 mg once a day, Crixotinib 250 mg and Sunitinib Cohort 2, Crixotinib (Xalkori) 250, Sunitinib (Sutent) 25.0, Crizotinib & Sunitinib 37.5 mg Cohort 3, Crizotinib (Xalkori) 250 mg, Sunitinib (Sutent) 37.5 mg
Mothaffar Rimawi
Breast Cancer
05/17
05/17

Download Options